These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 16447104)

  • 1. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
    Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of visceral leishmaniasis: Indian perspective.
    Agrawal S; Rai M; Sundar S
    J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
    Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
    Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
    Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
    J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
    Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
    J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.